PT3634468T - Composições sólidas para administração oral - Google Patents

Composições sólidas para administração oral

Info

Publication number
PT3634468T
PT3634468T PT187303441T PT18730344T PT3634468T PT 3634468 T PT3634468 T PT 3634468T PT 187303441 T PT187303441 T PT 187303441T PT 18730344 T PT18730344 T PT 18730344T PT 3634468 T PT3634468 T PT 3634468T
Authority
PT
Portugal
Prior art keywords
oral administration
solid compositions
compositions
solid
oral
Prior art date
Application number
PT187303441T
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59070439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3634468(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of PT3634468T publication Critical patent/PT3634468T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT187303441T 2017-06-09 2018-06-11 Composições sólidas para administração oral PT3634468T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17175131 2017-06-09

Publications (1)

Publication Number Publication Date
PT3634468T true PT3634468T (pt) 2023-03-28

Family

ID=59070439

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187303441T PT3634468T (pt) 2017-06-09 2018-06-11 Composições sólidas para administração oral

Country Status (28)

Country Link
US (2) US11167014B2 (pt)
EP (1) EP3634468B1 (pt)
JP (1) JP7239495B2 (pt)
KR (1) KR20200015564A (pt)
CN (1) CN110769846A (pt)
AR (1) AR112015A1 (pt)
AU (1) AU2018280875A1 (pt)
BR (1) BR112019025769A2 (pt)
CA (1) CA3064677A1 (pt)
CL (1) CL2019003402A1 (pt)
CO (1) CO2019013047A2 (pt)
DK (1) DK3634468T5 (pt)
ES (1) ES2938050T3 (pt)
FI (1) FI3634468T3 (pt)
HR (1) HRP20230075T1 (pt)
HU (1) HUE060962T2 (pt)
IL (1) IL270812B2 (pt)
MA (1) MA49253A (pt)
MX (1) MX2019013965A (pt)
MY (1) MY197488A (pt)
PE (1) PE20200606A1 (pt)
PH (1) PH12019550249A1 (pt)
PL (1) PL3634468T3 (pt)
PT (1) PT3634468T (pt)
RS (1) RS64045B1 (pt)
SI (1) SI3634468T1 (pt)
TW (1) TWI797133B (pt)
WO (1) WO2018224689A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102072202B1 (ko) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
RS58039B1 (sr) 2013-05-02 2019-02-28 Novo Nordisk As Oralno doziranje glp-1 jedinjenja
AR114353A1 (es) 2018-02-02 2020-08-26 Novo Nordisk As Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2020130502A1 (ko) * 2018-12-21 2020-06-25 (주)휴온스 엠파글리플로진 및 시타글립틴을 포함하는 약학적 조성물
WO2021023811A1 (en) * 2019-08-07 2021-02-11 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
JP2023502004A (ja) * 2019-11-07 2023-01-20 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬、ｓｇｌｔ２阻害剤、およびｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩を含む固形組成物
CN115461044B (zh) * 2020-04-29 2025-06-10 诺和诺德股份有限公司 包含glp-1激动剂和组氨酸的固体组合物
WO2023065231A1 (en) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
EP4456919A4 (en) * 2021-12-29 2025-10-08 Guangzhou Dazhou Biomedicine Ltd ORAL ADMINISTRATION
EP4299052A1 (en) * 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and a permeation enhancer
CN114984191B (zh) * 2022-07-04 2022-10-25 北京惠之衡生物科技有限公司 一种多肽类药物口服递送组合物
WO2024184352A1 (en) * 2023-03-06 2024-09-12 Ascendis Pharma A/S Drug compounds comprising albumin-binding moieties

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
AU3357800A (en) 1999-02-05 2000-08-25 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
AR059489A1 (es) 2006-02-15 2008-04-09 Boehringer Ingelheim Vetmed Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
MX2009002121A (es) 2006-09-07 2009-05-20 Hoffmann La Roche Proceso para la manufactura del acido n-(8-[2-hidroxibenzoil]-amin o)caprilico.
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
US20080287529A1 (en) 2007-05-18 2008-11-20 Bristol-Myers Squibb Company Crystal structures of sglt2 inhibitors and processes for preparing same
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
CN106075451A (zh) 2009-05-27 2016-11-09 阿斯利康(瑞典)有限公司 使用sglt2抑制剂及其组合物在对先前用其它抗糖尿病药进行的治疗具有耐受的患者中治疗ii型糖尿病的方法
CA3002948C (en) 2009-11-13 2020-10-27 Astrazeneca Uk Limited Immediate release tablet formulations
US20120329711A1 (en) 2009-12-16 2012-12-27 Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
MX377589B (es) * 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AU2012241894B2 (en) * 2011-04-12 2015-12-03 Novo Nordisk A/S Double-acylated GLP-1 derivatives
EP2747563A4 (en) 2011-08-26 2015-06-24 Aegis Therapeutics Llc COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION OF MEDICINAL PRODUCTS
KR102072202B1 (ko) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
WO2013189988A1 (en) * 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
US20160296602A1 (en) 2013-03-20 2016-10-13 Novo Nordisk A/S Dosing Regimen
WO2015155151A1 (en) 2014-04-07 2015-10-15 Novo Nordisk A/S Double-acylated glp-1 compounds
WO2017004623A1 (en) * 2015-07-02 2017-01-05 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
MA46890A (fr) 2016-11-28 2021-04-28 Novo Nordisk As Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme
WO2018096164A1 (en) 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
EP3544683A1 (en) 2016-11-28 2019-10-02 Novo Nordisk A/S Insulin degludec in cardiovascular conditions
WO2021023811A1 (en) * 2019-08-07 2021-02-11 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid

Also Published As

Publication number Publication date
IL270812B2 (en) 2024-01-01
RU2019139082A (ru) 2021-06-02
HUE060962T2 (hu) 2023-04-28
MY197488A (en) 2023-06-19
CO2019013047A2 (es) 2020-04-01
PH12019550249A1 (en) 2020-07-13
RS64045B1 (sr) 2023-04-28
SI3634468T1 (sl) 2023-02-28
WO2018224689A2 (en) 2018-12-13
MX2019013965A (es) 2020-01-23
PE20200606A1 (es) 2020-03-10
JP2020522559A (ja) 2020-07-30
JP7239495B2 (ja) 2023-03-14
FI3634468T3 (fi) 2023-02-19
DK3634468T3 (da) 2023-02-06
EP3634468B1 (en) 2022-12-14
HRP20230075T1 (hr) 2023-03-17
ES2938050T3 (es) 2023-04-04
KR20200015564A (ko) 2020-02-12
IL270812B1 (en) 2023-09-01
CL2019003402A1 (es) 2020-03-20
IL270812A (en) 2020-01-30
US20200147179A1 (en) 2020-05-14
US11167014B2 (en) 2021-11-09
EP3634468A2 (en) 2020-04-15
AU2018280875A1 (en) 2019-12-12
DK3634468T5 (da) 2024-09-02
CN110769846A (zh) 2020-02-07
PL3634468T3 (pl) 2023-03-13
BR112019025769A2 (pt) 2020-06-30
WO2018224689A3 (en) 2019-02-28
MA49253A (fr) 2020-04-15
AR112015A1 (es) 2019-09-11
TWI797133B (zh) 2023-04-01
RU2019139082A3 (pt) 2021-09-16
US20220016216A1 (en) 2022-01-20
CA3064677A1 (en) 2018-12-13
TW201904583A (zh) 2019-02-01

Similar Documents

Publication Publication Date Title
IL270812A (en) Solid compositions for oral drug administration
DK3720496T3 (en) Solid oral nicotine formulation
IL271657A (en) medical preparation
ZA201908454B (en) Solid preparation of cariprazine for oral administration
IL271759B1 (en) Pharmaceutical preparations that include anthraxtinib
GB201705303D0 (en) Pharmaceutical compositions
GB201804548D0 (en) Pharmaceutical compositions
GB201705304D0 (en) Pharmaceutical compositions
HUE061697T2 (hu) Stabil gyógyszerkészítmény orális adagolásra
SG11202001179YA (en) Pharmaceutical compositions
EP3290037A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
GB201705306D0 (en) Pharmaceutical compositions
GB201705305D0 (en) Pharmaceutical compositions
GB201808571D0 (en) Pharmaceutical compositions
GB201808567D0 (en) Pharmaceutical compositions
ZA202000014B (en) Pharmaceutical compositions
ZA201800096B (en) Oral care compositions
IL272044A (en) Pharmacy preparations
PT3377044T (pt) Composições de ibuprofeno para administração oral direta
GB201703483D0 (en) Dental compositions
IL272428A (en) pharmaceutical preparations
GB2561723B (en) A composition for oral administration
GB201810109D0 (en) Pharmaceutical compositions
GB201810261D0 (en) New pharmaceutical compositions
GB201810265D0 (en) New pharmaceutical compositions